Innocan Pharma's Breakthrough Review on Synthetic CBD for Chronic Pain

Innocan Pharma Corporation, recognized as a pioneer in the pharmaceutical and biotechnology sectors, has announced the publication of a significant peer-reviewed narrative review in Cureus journal. The article, titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review," delves into the therapeutic possibilities offered by long-acting synthetic cannabidiol (CBD) for chronic pain management. This issue is becoming increasingly urgent in a world where safe and effective treatment alternatives are desperately sought.

Co-authored by experts in pain management from esteemed institutions, including Johns Hopkins University and NYU School of Medicine, this review emphasizes that synthetic CBD, especially when administered using extended-release formulations, can serve as a non-opioid analgesic. The findings underline its potential to significantly lower the reliance on conventional harmful opioids.

Chronic pain impacts a staggering 24% of adults in the United States, leading to considerable challenges for individuals and healthcare systems alike. Treatment options currently available are often inadequate, with NSAIDs posing cumulative toxicity risks and opioids leading to severe issues such as tolerance, dependency, and overdose. Each year, opioid misuse leads to over 100,000 fatalities across the globe.

Recognizing this alarming trend, the U.S. Food and Drug Administration (FDA) has stressed the necessity of novel, non-addictive pain relief alternatives. Innocan's unique LPT-CBD platform aligns perfectly with this need. The LPT-CBD platform is an innovative injectable liposomal drug designed for the prolonged release of synthetic CBD, providing steady CBD levels in plasma for up to four weeks. This sustained release translates into long-lasting pain relief, making it a potentially advantageous substitute compared to existing opioid medications.

Regulatory submissions are currently being made to advance the LPT-CBD into human clinical trials, marking a crucial step towards introducing a first-in-class, non-opioid analgesic therapy suitable for complex chronic pain scenarios.

Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at Johns Hopkins University School of Medicine, remarked on the publication's importance, stating, "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy. Liposomal synthetic CBD could provide a safe and scalable solution for a variety of painful conditions."

Additionally, Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health, expressed optimism about CBD's potential, emphasizing the pressing requirement for effective alternatives to opioids amidst the ongoing addiction crisis.

Iris Bincovich, CEO of Innocan, expressed excitement over the publication, affirming the company’s commitment to progressing LPT-CBD towards clinical development. The goal is to offer an innovative and safe non-opioid analgesic solution for chronic pain management.

Innocan Pharma continues to lead the charge in developing groundbreaking pharmaceutical solutions, aiming to create a healthier and pain-free future. For further updates and insights into their progress, interested parties can explore Innocan's official website. For a deeper dive into the narrative review, you can access the article directly through its DOI link.

References:
1. Christo, P. J. et al. (2023). Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI 10.7759/cureus.81577
2. CDC, U.S. Senate Joint Economic Committee, The Lancet. "Opioid crisis addiction, overprescription, and insufficient primary prevention." The Lancet Regional Health – Americas 2023;23 100557.